Following U.S. Stocks may claim a “BIG Change” in the course of Today’s trading session: Hewlett-Packard Corporation (NYSE:HPQ), Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
At 9:50AM, Hewlett-Packard Corporation (NYSE:HPQ), with shares gained 0.71%, is now trading at $31.38, Sarepta Therapeutics, Inc. (NASDAQ:SRPT), with shares inclined 5.68%, is now trading at $14.03.
Headlines regarding these Stocks are depicted underneath:
Hewlett-Packard Corporation (NYSE:HPQ)
Hewlett-Packard Corporation (HPQ), was upgraded to “buy” from “hold” at Jefferies, which said the shares offer more noteworthy long-term value than is presently reflected in the stock’s price.
The company declared new software releases designed to assist organizations deliver mobile applications that delight customers and score 5-star ratings. The innovations harness HP’s unique assets in big data analytics, application lifecycle administration, IT operations administration and security to enable organizations to accelerate the delivery of every phase of the mobile app lifecycle, from creation and pre-production, to delivery and post-production administration.
Mobile applications are increasingly becoming the “front door” for a corporation’s brand, and future proceed and market share often depends on an end user’s immediate overall app experience. Mobile application users expect world-class performance, availability, security and quality, in addition to contextual understanding that delivers the right content at the right time.
However, delivering an enjoyable and useful user experience is a non-trivial task — mobile developers, testers, and IT administration must contend with a complex and constantly changing web of challenges. These comprise developing apps for a constantly expanding array of devices, operating systems, networks, and platforms, understanding and acting on the massive volumes of user and device data, and accurately predicting scale and usage levels to enable peak app experience.
HP’s latest innovations are designed to address these challenges by combining its proven assets in application development testing, monitoring and systems administration with HP Haven analytics, HP security software, and elegant SaaS-based interfaces. Together, these capabilities result in solutions that assist make designing, delivering, and managing mobile applications an intuitive, collaborative and fun process. Businesses can use HP’s solutions to accelerate application delivery, test and monitor apps across multiple devices and operating systems, and provide mobile users with exceptional and secure experiences.
HP creates new possibilities for technology to have a meaningful influence on people, businesses, governments and society. With the broadest technology portfolio spanning printing, personal systems, software, services and IT infrastructure, HP delivers solutions for customers’ most complex challenges in every region of the world.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. (SRPT), declared the appointment of Edward Kaye, M.D., the corporation’s Chief Medical Officer (CMO), as interim Chief Executive Officer (CEO) effective right away. He replaces Christopher Garabedian, who resigned as President and Chief Executive Officer and as a member of the Board, also effective right away. Dr. Kaye, who will continue in a dual capacity as CEO and CMO while the corporation conducts a search for a new full-time CEO, will focus his efforts on heading the regulatory and clinical process for the corporation’s lead product candidate, eteplirsen, and follow on “exon” drug candidates for Duchenne Muscular Dystrophy (DMD).
Dr. Kaye has been Sarepta’s CMO since June of 2011, during which time he has been responsible for the corporation’s medical and clinical operations. He was formerly Group Vice President of Clinical Development at Genzyme Corporation, one of the most successful biotechnology companies in the United States, from April 2007 to June 2011, where he supervised clinical development programs for rare diseases, counting lysosomal storage diseases and genetic neurological disorders. Preceding to this, Dr. Kaye held various roles at Genzyme Corporation since 2001, counting Vice President of Medical Affairs for Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs.
“We believe this change will facilitate the corporation’s clinical and regulatory discussions and relationships with the aim of meeting its stated timelines for bringing a potentially disease-modifying treatment to patients with DMD as soon as possible,” said John Hodgman, Sarepta’s interim Chairman of the Board. “Dr. Kaye has a proven track record of leading teams that have brought some of the most successful rare-disease drugs to market, counting Myozyme, Lumizyme and Fabrazyme. Further, he has excellent relationships with the clinical, regulatory and patient advocacy communities so critical to making this treatment a reality for this underserved patient population.”
Sarepta Therapeutics is a biopharmaceutical corporation focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Corporation is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, counting its lead DMD product candidate, eteplirsen, designed to skip exon 51.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
